212 related articles for article (PubMed ID: 35585646)
1. Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.
Zhou Z; Ding Z; Yuan J; Shen S; Jian H; Tan Q; Yang Y; Chen Z; Luo Q; Cheng X; Yu Y; Niu X; Qian L; Chen X; Gu L; Liu R; Ma S; Huang J; Chen T; Li Z; Ji W; Song L; Shen L; Jiang L; Yu Z; Zhang C; Tai Z; Wang C; Chen R; Carbone DP; Xia X; Lu S
J Hematol Oncol; 2022 May; 15(1):62. PubMed ID: 35585646
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
[TBL] [Abstract][Full Text] [Related]
3. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
[No Abstract] [Full Text] [Related]
4. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
5. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
7. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
[TBL] [Abstract][Full Text] [Related]
8.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
9. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
10. Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
Zeng A; Yin Y; Xu Z; Abuduwayiti A; Yang F; Shaik MS; Wang C; Chen K; Wang C; Fang X; Dai J
BMC Cancer; 2024 Mar; 24(1):396. PubMed ID: 38553708
[TBL] [Abstract][Full Text] [Related]
11. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
[TBL] [Abstract][Full Text] [Related]
12. Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma.
Zhou X; Xu R; Lu T; Xu R; Wang C; Peng B; Chang X; Shen Z; Wang K; Shi J; Zhao J; Zhang LY
Aging (Albany NY); 2023 Aug; 15(16):8090-8112. PubMed ID: 37578930
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
[TBL] [Abstract][Full Text] [Related]
14. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
Deng H; Zhao Y; Cai X; Chen H; Cheng B; Zhong R; Li F; Xiong S; Li J; Liu J; He J; Liang W
Crit Rev Oncol Hematol; 2022 Feb; 170():103582. PubMed ID: 35031441
[TBL] [Abstract][Full Text] [Related]
16. Signatures associated with homologous recombination deficiency and immune regulation to improve clinical outcomes in patients with lung adenocarcinoma.
Shang X; Qi K; Liu X; Liu Q; Zhang X; Wang D; Huang W
Front Oncol; 2022; 12():854999. PubMed ID: 36249053
[TBL] [Abstract][Full Text] [Related]
17. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
18. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
19. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
Hu J; Zhang L; Xia H; Yan Y; Zhu X; Sun F; Sun L; Li S; Li D; Wang J; Han Y; Zhang J; Bian D; Yu H; Chen Y; Fan P; Ma Q; Jiang G; Wang C; Zhang P
Genome Med; 2023 Mar; 15(1):14. PubMed ID: 36869384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
